Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on December 15, 2014, detailing a significant shift in its leadership and executive compensation structure. Notably, Dr. David Altshuler, a former board member, is transitioning to a key executive role as Executive Vice President, Global Research and Chief Scientific Officer, effective early 2015. This move signals a strong internal commitment to research and development leadership. Furthermore, the company announced an amendment to the employment agreement of its Chairman, President, and CEO, Dr. Jeffrey M. Leiden. This amendment extends his tenure through December 31, 2017, increases his base salary to $1.3 million effective January 1, 2015, and includes a performance-based restricted stock grant contingent on achieving positive EBITDA targets. These executive changes and compensation adjustments underscore the company's long-term strategic outlook and its focus on aligning executive incentives with financial performance.
Key Highlights
- 1Dr. David Altshuler resigns from the Board of Directors but will join the company as EVP, Global Research and Chief Scientific Officer in early 2015.
- 2Dr. Jeffrey M. Leiden's employment agreement as Chairman, President, and CEO has been extended through December 31, 2017.
- 3Dr. Leiden's annual base salary will increase from $1.1 million to $1.3 million, effective January 1, 2015.
- 4Dr. Leiden received a performance-based restricted stock grant of 125,000 shares.
- 5The stock grant vests on December 10, 2017, if positive EBITDA is achieved for the 12-month period ending September 30, 2017, or a later date if EBITDA targets are met between Q1 2018 and Q4 2019.
- 6The stock grant will terminate with a nominal repurchase price if still unvested by November 20, 2019.
- 7Exhibit 10.1 contains the full text of the First Amendment to Dr. Leiden's Employment Agreement.